Cocaine Addiction Clinical Trial
Official title:
Developing Computer Based Treatments for Addiction
The purpose of our research is to examine the promise of a new computer based approach to use in usual drug counseling when treating crack cocaine addiction.
This is the next part of the project under a National Institute of Drug Abuse-funded R01
treatment development study with the purpose of developing a computer-based augmentation of
standard drug counseling for cocaine dependence. This project has received additional
funding from NIDA. Specifically, the aims of the next part of the proposal are to develop
and manualize a cue-exposure based cocaine treatment using virtual reality (VR) based cue
exposure/extinction software and cellular phone-based computerized extinction reminder (CER)
technology for use in high-risk situations outside treatment sessions. We will enroll a
total of 270 cocaine dependent subjects in order to meet the target goal of 180 subjects in
treatment. This randomized clinical trial will be conducted in order to determine the
acceptability and feasibility of this treatment to subjects and therapists, and to obtain
treatment outcome effect size estimates. Specifically, during the next stage of the study,
180 cocaine dependent individuals will be randomly assigned to receive a NIDA approved
Individual/Group Drug Counseling (I/GDC) cocaine treatment or I/GDC plus VR/CER. Matching
between treatment groups will be based on age, sex, severity of crack use (using the
Addiction Severity Index), and presence or absence of antisocial personality disorder.
Treatment assignment will be conducted using a computerized urn matching program by the
off-site study statistician. Current psychiatric diagnoses will be assessed, as will changes
in crack use. Comprehensive assessments will be conducted during treatment at baseline, and
at a six-month and twelve-month follow-up. To measure outcomes, substance use will be
assessed via self-report and urinary analysis three times weekly during 24 weeks of active
treatment and weekly during six month and twelve month of follow-up assessment.
This new larger part of project follows work we have conducted in a NIDA-funded pilot
project over the past four years, developing the complementary intervention. In our
preliminary studies (Phase I a/b), we conducted focus groups, an open trial, and a small
randomized controlled trial (n = 53) to demonstrate the promise of the novel intervention.
The pilot phase I a/b portion enrolled 171 subjects (signed consent) at Duke. 19 of 53
completed the treatment portion. During Phase 1a, the VR and CER technology was developed
and refined using two small open clinical trials. At the conclusion of Phase 1a, a treatment
manual detailing the rationale and parameters of VR and CER technology was completed. Next,
as mentioned, a Phase Ib pilot randomized clinical trial was conducted in order to determine
the acceptability and feasibility of this treatment to patients and therapists, and to
obtain treatment outcome effect size estimates.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04336293 -
sTMS for Substance Use-disordered Veterans
|
N/A | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Completed |
NCT01822587 -
Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving
|
Phase 2 | |
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Completed |
NCT01651377 -
Pramipexole as a Treatment for Cocaine Dependence
|
Phase 1 | |
Completed |
NCT02768441 -
Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots
|
Early Phase 1 | |
Completed |
NCT02626494 -
Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction
|
Phase 4 | |
Recruiting |
NCT02892851 -
Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction.
|
N/A | |
Not yet recruiting |
NCT01319214 -
Reducing Drug Craving Memories
|
N/A | |
Recruiting |
NCT01259362 -
Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients
|
Phase 2 | |
Completed |
NCT01211418 -
Integrative Meditation (IM) for Cocaine Addiction
|
N/A | |
Recruiting |
NCT03423667 -
Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction
|
Phase 2 | |
Completed |
NCT01984177 -
Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence
|
N/A | |
Completed |
NCT01887366 -
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
|
Phase 2 | |
Completed |
NCT01337297 -
Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction
|
Phase 1/Phase 2 | |
Completed |
NCT01067846 -
Cognitive Enhancement and Relapse Prevention in Cocaine Addiction
|
N/A | |
Completed |
NCT01651364 -
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence
|
Phase 1 | |
Recruiting |
NCT03018236 -
Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.
|
Phase 4 | |
Completed |
NCT01929343 -
Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving
|
Phase 2 |